Emmanuel Somm
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Emmanuel Somm has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- François R. Jornayvaz
Service of Endocrinology, Diabetes and Metabolism, Department of Medicine, Geneva University Hospitals/University of Geneva, Geneva, Switzerland
7 shared publications Audrey Toulotte
Division of Development and Growth (E.S., A.T., P.S.H., M.L.A.), University of Geneva School of Medicine, 1211 Geneva 14, Switzerland
4 shared publications- Petra Susan Hüppi
Department of Paediatrics, Gynaecology and Obstetrics, University of Geneva, Geneva, Switzerland
4 shared publications Alberto Martinez
Syntaxin Ltd (R.J., A.M.), Abingdon OX14 3YS, United Kingdom
3 shared publicationsMichel L. Aubert
Division of Development and Growth (E.S., A.T., P.S.H., M.L.A.), University of Geneva School of Medicine, 1211 Geneva 14, Switzerland
3 shared publications- Nicolas Bonnet
Division of Bone Diseases, Department of Internal Medicine Specialties, Geneva University Hospital & Faculty of Medicine, Geneva, Switzerland
3 shared publications
Latest Publications
- Open Access
- 2 December 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1659227
Modulation of STAT6 signaling for hepatoprotection
Signal transducer and activator of transcription (STAT) proteins are a family of seven transcription factors mediating various biological processes. STAT6 is classically known to regulate immune cell biology by transmitting signals from interleukin (IL)-4 and IL-13 into transcriptional activation of genes driving type 2 immunity. In orchestrating T helper lymphocytes and macrophages polarization, STAT6 plays a central role in the regulation of both cellular and humoral immunities. Several pathologies, including inflammatory disorders, autoimmune/allergic diseases, metabolic syndrome as well as cancer, are associated with a dysregulation of type 2 immunity related to inadequate expression and/or activity of STAT6. In the present review, following a brief introduction of STAT6 biology, we summarize the immunologic and physiological roles of STAT6 in the context of liver integrity as well as the potential roles of STAT6-mediated pathways in both hepatoprotection and liver pathophysiological mechanisms.
- 2 December 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1659227
Open AccessModulation of STAT6 signaling for hepatoprotection
Signal transducer and activator of transcription (STAT) proteins are a family of seven transcription factors mediating various biological processes. STAT6 is classically known to regulate immune cell biology by transmitting signals from interleukin (IL)-4 and IL-13 into transcriptional activation of genes driving type 2 immunity. In orchestrating T helper lymphocytes and macrophages polarization, STAT6 plays a central role in the regulation of both cellular and humoral immunities. Several pathologies, including inflammatory disorders, autoimmune/allergic diseases, metabolic syndrome as well as cancer, are associated with a dysregulation of type 2 immunity related to inadequate expression and/or activity of STAT6. In the present review, following a brief introduction of STAT6 biology, we summarize the immunologic and physiological roles of STAT6 in the context of liver integrity as well as the potential roles of STAT6-mediated pathways in both hepatoprotection and liver pathophysiological mechanisms.
- Open Access
- 20 November 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (12)
Interleukin-18 binding protein protects against metabolic steatohepatitis
Background: Metabolic dysfunction–associated steatohepatitis (MASH) is a frequent consequence of Western diet consumption and liver steatosis. IL-18 binding protein (IL-18BP) limits the action of interleukin-18 (IL-18). Our work aims to study the unknown role of IL-18BP in MASH progression. Methods: We analyzed the liver transcriptome from MASH patients. We investigated cell-specific expressions of IL-18, IL-18BP, and IL-18 receptor in human and mouse liver. We studied the liver phenotype of Il18bp −/− mice on a high-fat/high-cholesterol (HFHC) diet. We administered an anti-IL-18 antibody in Il18bp −/− mice and in diet-induced wild-type (WT) MASH mice. We generated and studied double knock-out Il18bp −/− Ifng −/− mice. Results: IL-18BP expression is increased in the liver of patients and mouse models with MASH and positively correlates with fibrosis stages. On the HFHC diet, Il18bp −/− mice exhibit increased hepatic damage, inflammation, and fibrosis compared with WT mice. Treatment with anti-IL-18 antibody corrects liver defects in Il18bp −/− mice and ameliorates inflammation and fibrosis in diet-induced MASH mice, suggesting a translational treatment opportunity. Genetic deficiency in IFN-γ abrogates inflammation but not fibrosis in Il18bp −/− mice. Conclusions: IL-18BP has a role in limiting the progression of MASH, notably by reducing inflammation and fibrosis. Downstream IL-18 over-signaling, IFN-γ, mediates inflammation, but not fibrosis. Increasing IL-18BP levels represents a novel therapeutic perspective for patients affected by MASH.
- 20 November 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (12)
Open AccessInterleukin-18 binding protein protects against metabolic steatohepatitis
Background: Metabolic dysfunction–associated steatohepatitis (MASH) is a frequent consequence of Western diet consumption and liver steatosis. IL-18 binding protein (IL-18BP) limits the action of interleukin-18 (IL-18). Our work aims to study the unknown role of IL-18BP in MASH progression. Methods: We analyzed the liver transcriptome from MASH patients. We investigated cell-specific expressions of IL-18, IL-18BP, and IL-18 receptor in human and mouse liver. We studied the liver phenotype of Il18bp −/− mice on a high-fat/high-cholesterol (HFHC) diet. We administered an anti-IL-18 antibody in Il18bp −/− mice and in diet-induced wild-type (WT) MASH mice. We generated and studied double knock-out Il18bp −/− Ifng −/− mice. Results: IL-18BP expression is increased in the liver of patients and mouse models with MASH and positively correlates with fibrosis stages. On the HFHC diet, Il18bp −/− mice exhibit increased hepatic damage, inflammation, and fibrosis compared with WT mice. Treatment with anti-IL-18 antibody corrects liver defects in Il18bp −/− mice and ameliorates inflammation and fibrosis in diet-induced MASH mice, suggesting a translational treatment opportunity. Genetic deficiency in IFN-γ abrogates inflammation but not fibrosis in Il18bp −/− mice. Conclusions: IL-18BP has a role in limiting the progression of MASH, notably by reducing inflammation and fibrosis. Downstream IL-18 over-signaling, IFN-γ, mediates inflammation, but not fibrosis. Increasing IL-18BP levels represents a novel therapeutic perspective for patients affected by MASH.
- Open Access
- 11 October 2025
- Published by Elsevier in JHEP Reports
- Vol. 8 (1)
Interleukin-18 binding protein deficiency results in gut microbiota dysbiosis and aggravated diet-induced MASH in mice
- 11 October 2025
- Published by Elsevier in JHEP Reports
- Vol. 8 (1)
Open AccessInterleukin-18 binding protein deficiency results in gut microbiota dysbiosis and aggravated diet-induced MASH in mice
- Open Access
Tissular glucocorticoid reactivating enzyme 11β-HSD1 drives pathogenic myofibroblast differentiation in chronic kidney disease
Chronic kidney disease (CKD) is a growing public health crisis, affecting over 10% of the global population and significantly increasing mortality and morbidity. Irrespective of its underlying cause, tubulointerstitial fibrosis (TIF) is a hallmark of CKD progression, with myofibroblasts being the primary effectors of renal fibrosis. Here, we show that 11beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is a critical driver of pathogenic myofibroblast differentiation and fibrosis in CKD. Using genetic deletion and pharmacological inhibition of 11β-HSD1 in mouse models, we demonstrate a marked reduction in TIF severity and improved renal function, linked to the suppression of a regulatory myofibroblast (Reg-MF) subpopulation. Single-cell and spatial transcriptomics data reveal that 11β-HSD1 is essential for the activation and expansion of Reg-MFs, which is conserved across species and predicts worse outcomes in CKD patients and kidney allograft recipients. These findings establish a direct link between 11β-HSD1 activity and renal fibrogenesis, highlighting its role during the transition from pericytes to pathogenic Reg-MFs. Our results support 11β-HSD1 inhibition as a promising therapeutic strategy to mitigate CKD progression, offering both mechanistic insights and translational potential for improving patient outcomes.
Open AccessTissular glucocorticoid reactivating enzyme 11β-HSD1 drives pathogenic myofibroblast differentiation in chronic kidney disease
Chronic kidney disease (CKD) is a growing public health crisis, affecting over 10% of the global population and significantly increasing mortality and morbidity. Irrespective of its underlying cause, tubulointerstitial fibrosis (TIF) is a hallmark of CKD progression, with myofibroblasts being the primary effectors of renal fibrosis. Here, we show that 11beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is a critical driver of pathogenic myofibroblast differentiation and fibrosis in CKD. Using genetic deletion and pharmacological inhibition of 11β-HSD1 in mouse models, we demonstrate a marked reduction in TIF severity and improved renal function, linked to the suppression of a regulatory myofibroblast (Reg-MF) subpopulation. Single-cell and spatial transcriptomics data reveal that 11β-HSD1 is essential for the activation and expansion of Reg-MFs, which is conserved across species and predicts worse outcomes in CKD patients and kidney allograft recipients. These findings establish a direct link between 11β-HSD1 activity and renal fibrogenesis, highlighting its role during the transition from pericytes to pathogenic Reg-MFs. Our results support 11β-HSD1 inhibition as a promising therapeutic strategy to mitigate CKD progression, offering both mechanistic insights and translational potential for improving patient outcomes.
- Open Access
- 5 November 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (22) , 11875
Linking Antibodies Against Apolipoprotein A-1 to Metabolic Dysfunction-Associated Steatohepatitis in Mice
Metabolic dysfunction-associated fatty liver disease (MASLD) is a common liver and health issue associated with heightened cardiovascular disease (CVD) risk, with Cytokeratin 18 (CK-18) as a marker of liver injury across the MASLD to cirrhosis spectrum. Autoantibodies against apolipoprotein A-1 (AAA-1s) predict increased CVD risk, promoting atherosclerosis and liver steatosis in apoE−/− mice, though their impact on liver inflammation and fibrosis remains unclear. This study examined AAA-1s’ impact on low-grade inflammation, liver steatosis, and fibrosis using a MASLD mouse model exposed to AAA-1s passive immunization (PI). Ten-week-old male C57BL/6J mice under a high-fat diet underwent PI with AAA-1s or control antibodies for ten days. Compared to controls, AAA-1-immunized mice showed higher plasma CK-18 (5.3 vs. 2.1 pg/mL, p = 0.031), IL-6 (13 vs. 6.9 pg/mL, p = 0.035), IL-10 (27.3 vs. 9.8 pg/mL, p = 0.007), TNF-α (32.1 vs. 24.2 pg/mL, p = 0.032), and liver steatosis (93.4% vs. 73.8%, p = 0.007). Transcriptomic analyses revealed hepatic upregulation of pro-fibrotic mRNAs in AAA-1-recipient mice, though histological changes were absent. In conclusion, short-term AAA-1 PI exacerbated liver steatosis, inflammation, and pro-fibrotic gene expression, suggesting that AAA-1s may play a role in MASLD progression. Further research with prolonged AAA-1 exposure is warranted to clarify their potential role in liver fibrosis and associated complications.
- 5 November 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (22) , 11875
Open AccessLinking Antibodies Against Apolipoprotein A-1 to Metabolic Dysfunction-Associated Steatohepatitis in Mice
Metabolic dysfunction-associated fatty liver disease (MASLD) is a common liver and health issue associated with heightened cardiovascular disease (CVD) risk, with Cytokeratin 18 (CK-18) as a marker of liver injury across the MASLD to cirrhosis spectrum. Autoantibodies against apolipoprotein A-1 (AAA-1s) predict increased CVD risk, promoting atherosclerosis and liver steatosis in apoE−/− mice, though their impact on liver inflammation and fibrosis remains unclear. This study examined AAA-1s’ impact on low-grade inflammation, liver steatosis, and fibrosis using a MASLD mouse model exposed to AAA-1s passive immunization (PI). Ten-week-old male C57BL/6J mice under a high-fat diet underwent PI with AAA-1s or control antibodies for ten days. Compared to controls, AAA-1-immunized mice showed higher plasma CK-18 (5.3 vs. 2.1 pg/mL, p = 0.031), IL-6 (13 vs. 6.9 pg/mL, p = 0.035), IL-10 (27.3 vs. 9.8 pg/mL, p = 0.007), TNF-α (32.1 vs. 24.2 pg/mL, p = 0.032), and liver steatosis (93.4% vs. 73.8%, p = 0.007). Transcriptomic analyses revealed hepatic upregulation of pro-fibrotic mRNAs in AAA-1-recipient mice, though histological changes were absent. In conclusion, short-term AAA-1 PI exacerbated liver steatosis, inflammation, and pro-fibrotic gene expression, suggesting that AAA-1s may play a role in MASLD progression. Further research with prolonged AAA-1 exposure is warranted to clarify their potential role in liver fibrosis and associated complications.
- Open Access
NADPH oxidases in healthy white adipose tissue and in obesity: function, regulation, and clinical implications
Reactive oxygen species, when produced in a controlled manner, are physiological modulators of healthy white adipose tissue (WAT) expansion and metabolic function. By contrast, unbridled production of oxidants is associated with pathological WAT expansion and the establishment of metabolic dysfunctions, most notably insulin resistance and type 2 diabetes mellitus. NADPH oxidases (NOXs) produce oxidants in an orderly fashion and are present in adipocytes and in other diverse WAT‐constituent cell types. Recent studies have established several links between aberrant NOX‐derived oxidant production, adiposity, and metabolic homeostasis. The objective of this review is to highlight the physiological roles attributed to diverse NOX isoforms in healthy WAT and summarize current knowledge of the metabolic consequences related to perturbations in their adequate oxidant production. We detail WAT‐related alterations in preclinical investigations conducted in NOX‐deficient murine models. In addition, we review clinical studies that have employed NOX inhibitors and currently available data related to human NOX mutations in metabolic disturbances. Future investigations aimed at understanding the integration of NOX‐derived oxidants in the regulation of the WAT cellular redox network are essential for designing successful redox‐related precision therapies to curb obesity and attenuate obesity‐associated metabolic pathologies.
Open AccessNADPH oxidases in healthy white adipose tissue and in obesity: function, regulation, and clinical implications
Reactive oxygen species, when produced in a controlled manner, are physiological modulators of healthy white adipose tissue (WAT) expansion and metabolic function. By contrast, unbridled production of oxidants is associated with pathological WAT expansion and the establishment of metabolic dysfunctions, most notably insulin resistance and type 2 diabetes mellitus. NADPH oxidases (NOXs) produce oxidants in an orderly fashion and are present in adipocytes and in other diverse WAT‐constituent cell types. Recent studies have established several links between aberrant NOX‐derived oxidant production, adiposity, and metabolic homeostasis. The objective of this review is to highlight the physiological roles attributed to diverse NOX isoforms in healthy WAT and summarize current knowledge of the metabolic consequences related to perturbations in their adequate oxidant production. We detail WAT‐related alterations in preclinical investigations conducted in NOX‐deficient murine models. In addition, we review clinical studies that have employed NOX inhibitors and currently available data related to human NOX mutations in metabolic disturbances. Future investigations aimed at understanding the integration of NOX‐derived oxidants in the regulation of the WAT cellular redox network are essential for designing successful redox‐related precision therapies to curb obesity and attenuate obesity‐associated metabolic pathologies.
- Open Access
- 12 October 2022
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 13, 971745
Interleukin-18 in metabolism: From mice physiology to human diseases
Interleukin-18 (IL-18) is a classical member of the IL-1 superfamily of cytokines. As IL-1β, IL-18 precursor is processed by inflammasome/caspase-1 into a mature and biologically active form. IL-18 binds to its specific receptor composed of two chains (IL-18Rα and IL-18Rβ) to trigger a similar intracellular signaling pathway as IL-1, ultimately leading to activation of NF-κB and inflammatory processes. Independently of this IL-1-like signaling, IL-18 also specifically induces IFN-γ production, driving the Th1 immune response. In circulation, IL-18 binds to the IL-18 binding protein (IL-18BP) with high affinity, letting only a small fraction of free IL-18 able to trigger receptor-mediated signaling. In contrast to other IL-1 family members, IL-18 is produced constitutively by different cell types, suggesting implications in normal physiology. If the roles of IL-18 in inflammatory processes and infectious diseases are well described, recent experimental studies in mice have highlighted the action of IL-18 signaling in the control of energy homeostasis, pancreatic islet immunity and liver integrity during nutritional stress. At the same time, clinical observations implicate IL-18 in various metabolic diseases including obesity, type 1 and 2 diabetes and nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH). In the present review, we summarize and discuss both the physiological actions of IL-18 in metabolism and its potential roles in pathophysiological mechanisms leading to the most common human metabolic disorders, such as obesity, diabetes and NAFLD/NASH.
- 12 October 2022
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 13, 971745
Open AccessInterleukin-18 in metabolism: From mice physiology to human diseases
Interleukin-18 (IL-18) is a classical member of the IL-1 superfamily of cytokines. As IL-1β, IL-18 precursor is processed by inflammasome/caspase-1 into a mature and biologically active form. IL-18 binds to its specific receptor composed of two chains (IL-18Rα and IL-18Rβ) to trigger a similar intracellular signaling pathway as IL-1, ultimately leading to activation of NF-κB and inflammatory processes. Independently of this IL-1-like signaling, IL-18 also specifically induces IFN-γ production, driving the Th1 immune response. In circulation, IL-18 binds to the IL-18 binding protein (IL-18BP) with high affinity, letting only a small fraction of free IL-18 able to trigger receptor-mediated signaling. In contrast to other IL-1 family members, IL-18 is produced constitutively by different cell types, suggesting implications in normal physiology. If the roles of IL-18 in inflammatory processes and infectious diseases are well described, recent experimental studies in mice have highlighted the action of IL-18 signaling in the control of energy homeostasis, pancreatic islet immunity and liver integrity during nutritional stress. At the same time, clinical observations implicate IL-18 in various metabolic diseases including obesity, type 1 and 2 diabetes and nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH). In the present review, we summarize and discuss both the physiological actions of IL-18 in metabolism and its potential roles in pathophysiological mechanisms leading to the most common human metabolic disorders, such as obesity, diabetes and NAFLD/NASH.
- Open Access
- 1 January 2021
- Published by Elsevier in Translational Research
- Vol. 227, 75-88
The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet
- 1 January 2021
- Published by Elsevier in Translational Research
- Vol. 227, 75-88
Open AccessThe GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet
- Open Access
- 1 November 2018
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 315 (5) , E833-E847
β-Klotho deficiency shifts the gut-liver bile acid axis and induces hepatic alterations in mice
β-Klotho (encoded by Klb) is an obligate coreceptor, mediating both fibroblast growth factor (FGF)15 and FGF21 signaling. Klb−/−mice are refractory to metabolic FGF15 and FGF21 action and exhibit derepressed (increased) bile acid (BA) synthesis. Here, we deeply phenotyped male Klb−/−mice on a pure C57BL/6J genetic background, fed a chow diet focusing on metabolic aspects. This aims to better understand the physiological consequences of concomitant FGF15 and FGF21 signaling deficiency, in particular on the gut-liver axis. Klb−/−mice present permanent growth restriction independent of adiposity and energy balance. Klb−/−mice also exhibit few changes in carbohydrate metabolism, combining normal gluco-tolerance, insulin sensitivity, and fasting response with increased gluconeogenic capacity and decreased glycogen mobilization. Livers of Klb−/−mice reveal pathologic features, including a proinflammatory status and initiation of fibrosis. These defects are associated to a massive shift in BA composition in the enterohepatic system and blood circulation featured by a large excess of microbiota-derived deoxycholic acid, classically known for its genotoxicity in the gastrointestinal tract. In conclusion, β-Klotho is a gatekeeper of hepatic integrity through direct action (mediating FGF21 anti-inflammatory signaling) and indirect mechanisms (mediating FGF15 signaling that maintains BA level and composition).
- 1 November 2018
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 315 (5) , E833-E847
Open Accessβ-Klotho deficiency shifts the gut-liver bile acid axis and induces hepatic alterations in mice
β-Klotho (encoded by Klb) is an obligate coreceptor, mediating both fibroblast growth factor (FGF)15 and FGF21 signaling. Klb−/−mice are refractory to metabolic FGF15 and FGF21 action and exhibit derepressed (increased) bile acid (BA) synthesis. Here, we deeply phenotyped male Klb−/−mice on a pure C57BL/6J genetic background, fed a chow diet focusing on metabolic aspects. This aims to better understand the physiological consequences of concomitant FGF15 and FGF21 signaling deficiency, in particular on the gut-liver axis. Klb−/−mice present permanent growth restriction independent of adiposity and energy balance. Klb−/−mice also exhibit few changes in carbohydrate metabolism, combining normal gluco-tolerance, insulin sensitivity, and fasting response with increased gluconeogenic capacity and decreased glycogen mobilization. Livers of Klb−/−mice reveal pathologic features, including a proinflammatory status and initiation of fibrosis. These defects are associated to a massive shift in BA composition in the enterohepatic system and blood circulation featured by a large excess of microbiota-derived deoxycholic acid, classically known for its genotoxicity in the gastrointestinal tract. In conclusion, β-Klotho is a gatekeeper of hepatic integrity through direct action (mediating FGF21 anti-inflammatory signaling) and indirect mechanisms (mediating FGF15 signaling that maintains BA level and composition).
- 14 August 2018
- Published by The Endocrine Society in Endocrine Reviews
- Vol. 39 (6) , 960-989
Fibroblast Growth Factor 15/19: From Basic Functions to Therapeutic Perspectives
Discovered 20 years ago, Fibroblast Growth Factor (FGF) 19, and its mouse ortholog FGF15, were the first members of a new subfamily of FGFs able to act as hormones. During fetal life, FGF15/19 is involved in organogenesis, affecting the development of the ear, eye, heart and brain. At adulthood, FGF15/19 is mainly produced by the ileum, acting on the liver to repress hepatic bile acid synthesis and promote postprandial nutrient partitioning. In rodents, pharmacologic doses of FGF19 induce the same anti-obesity and anti-diabetic actions as FGF21, these metabolic effects being partly mediated by the brain. However, activation of hepatocyte proliferation by FGF19 has long been a challenge to its therapeutic use. Recently, genetic reengineering of the molecule has resolved this issue. Despite a global overlap in expression pattern and function, murine FGF15 and human FGF19 exhibit several differences in terms of regulation, molecular structure, signaling and biological properties. As most of the knowledge originates from the use of FGF19 in murine models, differences between mice and humans in the biology of FGF15/19 have to be considered for a successful translation from bench to bedside. This review summarizes the basic knowledge concerning FGF15/19 in mice and humans, with a special focus on regulation of production, morphogenic properties, hepatocyte growth, bile acid homeostasis, as well as actions on glucose, lipid and energy homeostasis. Moreover, implications and therapeutic perspectives concerning FGF19 in human diseases (including obesity, type 2 diabetes, hepatic steatosis, biliary disorders and cancer) are also discussed.
- 14 August 2018
- Published by The Endocrine Society in Endocrine Reviews
- Vol. 39 (6) , 960-989
Fibroblast Growth Factor 15/19: From Basic Functions to Therapeutic Perspectives
Discovered 20 years ago, Fibroblast Growth Factor (FGF) 19, and its mouse ortholog FGF15, were the first members of a new subfamily of FGFs able to act as hormones. During fetal life, FGF15/19 is involved in organogenesis, affecting the development of the ear, eye, heart and brain. At adulthood, FGF15/19 is mainly produced by the ileum, acting on the liver to repress hepatic bile acid synthesis and promote postprandial nutrient partitioning. In rodents, pharmacologic doses of FGF19 induce the same anti-obesity and anti-diabetic actions as FGF21, these metabolic effects being partly mediated by the brain. However, activation of hepatocyte proliferation by FGF19 has long been a challenge to its therapeutic use. Recently, genetic reengineering of the molecule has resolved this issue. Despite a global overlap in expression pattern and function, murine FGF15 and human FGF19 exhibit several differences in terms of regulation, molecular structure, signaling and biological properties. As most of the knowledge originates from the use of FGF19 in murine models, differences between mice and humans in the biology of FGF15/19 have to be considered for a successful translation from bench to bedside. This review summarizes the basic knowledge concerning FGF15/19 in mice and humans, with a special focus on regulation of production, morphogenic properties, hepatocyte growth, bile acid homeostasis, as well as actions on glucose, lipid and energy homeostasis. Moreover, implications and therapeutic perspectives concerning FGF19 in human diseases (including obesity, type 2 diabetes, hepatic steatosis, biliary disorders and cancer) are also discussed.